305 related articles for article (PubMed ID: 28913005)
1. Chaperone-Based Therapies for Disease Modification in Parkinson's Disease.
Friesen EL; De Snoo ML; Rajendran L; Kalia LV; Kalia SK
Parkinsons Dis; 2017; 2017():5015307. PubMed ID: 28913005
[TBL] [Abstract][Full Text] [Related]
2. Dysfunction of Cellular Proteostasis in Parkinson's Disease.
Lehtonen Š; Sonninen TM; Wojciechowski S; Goldsteins G; Koistinaho J
Front Neurosci; 2019; 13():457. PubMed ID: 31133790
[TBL] [Abstract][Full Text] [Related]
3. Molecular chaperones in Parkinson's disease--present and future.
Ebrahimi-Fakhari D; Wahlster L; McLean PJ
J Parkinsons Dis; 2011; 1(4):299-320. PubMed ID: 22279517
[TBL] [Abstract][Full Text] [Related]
4. Molecular chaperones as rational drug targets for Parkinson's disease therapeutics.
Kalia SK; Kalia LV; McLean PJ
CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):741-53. PubMed ID: 20942788
[TBL] [Abstract][Full Text] [Related]
5. Molecular targets for modulating the protein translation vital to proteostasis and neuron degeneration in Parkinson's disease.
Zhou ZD; Selvaratnam T; Lee JCT; Chao YX; Tan EK
Transl Neurodegener; 2019; 8():6. PubMed ID: 30740222
[TBL] [Abstract][Full Text] [Related]
6. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
Chaari A; Hoarau-Véchot J; Ladjimi M
Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
[TBL] [Abstract][Full Text] [Related]
7. Molecular chaperones and protein folding as therapeutic targets in Parkinson's disease and other synucleinopathies.
Ebrahimi-Fakhari D; Saidi LJ; Wahlster L
Acta Neuropathol Commun; 2013 Dec; 1(1):79. PubMed ID: 24314025
[TBL] [Abstract][Full Text] [Related]
8. The disturbance of protein synthesis/degradation homeostasis is a common trait of age-related neurodegenerative disorders.
Di Domenico F; Lanzillotta C
Adv Protein Chem Struct Biol; 2022; 132():49-87. PubMed ID: 36088079
[TBL] [Abstract][Full Text] [Related]
9. Proteostasis and the Regulation of Intra- and Extracellular Protein Aggregation by ATP-Independent Molecular Chaperones: Lens α-Crystallins and Milk Caseins.
Carver JA; Ecroyd H; Truscott RJW; Thorn DC; Holt C
Acc Chem Res; 2018 Mar; 51(3):745-752. PubMed ID: 29442498
[TBL] [Abstract][Full Text] [Related]
10. LRRK2 and Proteostasis in Parkinson's Disease.
Pérez-Carrión MD; Posadas I; Solera J; Ceña V
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743250
[TBL] [Abstract][Full Text] [Related]
11. Protein Quality Control by Molecular Chaperones in Neurodegeneration.
Ciechanover A; Kwon YT
Front Neurosci; 2017; 11():185. PubMed ID: 28428740
[TBL] [Abstract][Full Text] [Related]
12. Pathogenesis of Parkinson's disease: emerging role of molecular chaperones.
Bandopadhyay R; de Belleroche J
Trends Mol Med; 2010 Jan; 16(1):27-36. PubMed ID: 20036196
[TBL] [Abstract][Full Text] [Related]
13. Uncovering the Role of Natural and Synthetic Small Molecules in Counteracting the Burden of α-Synuclein Aggregates and Related Toxicity in Different Models of Parkinson's Disease.
Mohammed S; Russo I; Ramazzina I
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686175
[TBL] [Abstract][Full Text] [Related]
14. Challenging Proteostasis: Role of the Chaperone Network to Control Aggregation-Prone Proteins in Human Disease.
Sinnige T; Yu A; Morimoto RI
Adv Exp Med Biol; 2020; 1243():53-68. PubMed ID: 32297211
[TBL] [Abstract][Full Text] [Related]
15. Chaperones and Proteostasis: Role in Parkinson's Disease.
Joshi N; Raveendran A; Nagotu S
Diseases; 2020 Jun; 8(2):. PubMed ID: 32580484
[TBL] [Abstract][Full Text] [Related]
16. Rescue of α-synuclein aggregation in Parkinson's patient neurons by synergistic enhancement of ER proteostasis and protein trafficking.
Stojkovska I; Wani WY; Zunke F; Belur NR; Pavlenko EA; Mwenda N; Sharma K; Francelle L; Mazzulli JR
Neuron; 2022 Feb; 110(3):436-451.e11. PubMed ID: 34793693
[TBL] [Abstract][Full Text] [Related]
17. Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations.
Lang AE; Espay AJ
Mov Disord; 2018 May; 33(5):660-677. PubMed ID: 29644751
[TBL] [Abstract][Full Text] [Related]
18. Molecular chaperones and Parkinson's disease.
Hu S; Tan J; Qin L; Lv L; Yan W; Zhang H; Tang B; Wang C
Neurobiol Dis; 2021 Dec; 160():105527. PubMed ID: 34626793
[TBL] [Abstract][Full Text] [Related]
19. Expanding role of molecular chaperones in regulating α-synuclein misfolding; implications in Parkinson's disease.
Sharma SK; Priya S
Cell Mol Life Sci; 2017 Feb; 74(4):617-629. PubMed ID: 27522545
[TBL] [Abstract][Full Text] [Related]
20. Targeting Chaperone/Co-Chaperone Interactions with Small Molecules: A Novel Approach to Tackle Neurodegenerative Diseases.
Wang L; Bergkvist L; Kumar R; Winblad B; Pavlov PF
Cells; 2021 Sep; 10(10):. PubMed ID: 34685574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
